Seoul Pharma Co. Ltd (018680) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.064x

Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has a cash flow conversion efficiency ratio of -0.064x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.66 Billion ≈ $-1.80 Million USD) by net assets (₩41.30 Billion ≈ $27.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Seoul Pharma Co. Ltd (018680) market capitalisation for the company's overall valuation and market capitalisation.

Seoul Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Seoul Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Seoul Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoul Pharma Co. Ltd ranked by their cash flow conversion efficiency. Explore 018680 operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
DT&C Co. Ltd KQ:187220	0.028x
Sapura Industrial Bhd KLSE:7811	0.000x
JPMorgan Japanese Investment Trust LSE:JFJ	0.003x
Domo Activos Socimi SA MC:DOMO	-0.014x
Macompta Fr Sa PA:MLMCA	N/A
Geratherm Medical AG XETRA:GME	0.021x
Volution Group plc LSE:FAN	0.147x
Deltamac Taiwan Co Ltd TWO:6144	0.006x

Annual Cash Flow Conversion Efficiency for Seoul Pharma Co. Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Seoul Pharma Co. Ltd from 2012 to 2024. View Seoul Pharma Co. Ltd share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩40.17 Billion ≈ $27.22 Million	₩-3.01 Billion ≈ $-2.04 Million	-0.075x	-154.86%
2023-12-31	₩38.56 Billion ≈ $26.13 Million	₩5.26 Billion ≈ $3.57 Million	0.137x	+6282.46%
2022-12-31	₩35.42 Billion ≈ $24.00 Million	₩-78.21 Million ≈ $-53.01K	-0.002x	+97.50%
2021-12-31	₩18.96 Billion ≈ $12.85 Million	₩-1.67 Billion ≈ $-1.13 Million	-0.088x	-144.43%
2020-12-31	₩28.85 Billion ≈ $19.55 Million	₩5.74 Billion ≈ $3.89 Million	0.199x	+93.15%
2019-12-31	₩28.45 Billion ≈ $19.28 Million	₩2.93 Billion ≈ $1.98 Million	0.103x	+522.01%
2018-12-31	₩50.31 Billion ≈ $34.10 Million	₩-1.23 Billion ≈ $-831.74K	-0.024x	-15.51%
2017-12-31	₩53.86 Billion ≈ $36.50 Million	₩-1.14 Billion ≈ $-770.77K	-0.021x	+53.00%
2016-12-31	₩42.07 Billion ≈ $28.51 Million	₩-1.89 Billion ≈ $-1.28 Million	-0.045x	-205.98%
2015-12-31	₩33.53 Billion ≈ $22.72 Million	₩1.42 Billion ≈ $963.32K	0.042x	-10.82%
2014-12-31	₩31.10 Billion ≈ $21.08 Million	₩1.48 Billion ≈ $1.00 Million	0.048x	+460.77%
2013-12-31	₩32.25 Billion ≈ $21.86 Million	₩-425.00 Million ≈ $-288.02K	-0.013x	-103.63%
2012-12-31	₩25.38 Billion ≈ $17.20 Million	₩9.22 Billion ≈ $6.25 Million	0.363x	--

About Seoul Pharma Co. Ltd

KQ:018680 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$15.52 Million

₩22.90 Billion KRW

Market Cap Rank

#25988 Global

#1949 in Korea

Share Price

₩1964.00

Change (1 day)

-0.51%

52-Week Range

₩1932.00 - ₩3230.00

All Time High

₩17976.69